ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
7.80
+0.48 (6.56%)
Jun 24, 2026, 4:00 PM EDT - Market closed
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $8.17 billion as of June 24, 2026. Its market cap has increased by 169.06% in one year.
Market Cap
8.17B
Enterprise Value
8.90B
1-Year Change
169.06%
Ranking
Category
Stock Price
$7.80
Market Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $8.17B, a decrease of -44.89%. That is a compound annual growth rate of -10.65%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 24, 2026 | 8.16B | 318.35% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Corcept Therapeutics | 8.57B |
| Praxis Precision Medicines | 8.51B |
| Spyre Therapeutics | 8.43B |
| Halozyme Therapeutics | 8.26B |
| Kymera Therapeutics | 8.08B |
| ABIVAX Société Anonyme | 7.77B |
| Immunovant | 7.72B |
| Protagonist Therapeutics | 7.65B |